upadacitinib
Selected indexed studies
- Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. (N Engl J Med, 2023) [PMID:37224198]
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. (JAMA Dermatol, 2021) [PMID:34347860]
- Upadacitinib: Mechanism of action, clinical, and translational science. (Clin Transl Sci, 2024) [PMID:37984057]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. (2023) pubmed
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. (2021) pubmed
- Upadacitinib: Mechanism of action, clinical, and translational science. (2024) pubmed
- A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis. (2025) pubmed
- Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis. (2024) pubmed
- Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. (2021) pubmed
- Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. (2022) pubmed
- Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. (2019) pubmed
- Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. (2021) pubmed
- Upadacitinib for Acute Severe Ulcerative Colitis: A Systematic Review. (2025) pubmed